DUPIXENT is not a steroid. DUPIXENT is a biologic and can help reduce your patients' use of systemic corticosteroids. In SINUS-24 and SINUS-52, 74% fewer patients required SCS use at Week 52 with DUPIXENT 300 mg Q2W + INCS compared to placebo + INCS (HR: 0.26 [95% CI: 0.18, 0.38]). In those same trials, SCS courses were reduced by 75% per year (RR: 0.25 [95% CI: 0.17, 0.37]).1

DUPIXENT provided a 76% reduction in SCS use or CRSwNP surgery at Week 52 with DUPIXENT 300 mg Q2W + INCS vs placebo + INCS (HR: 0.24 [95% CI: 0.17, 0.35]).

Individually, SCS reduction was not a multiplicity-adjusted endpoint.

HR, hazard ratio; INCS, intranasal corticosteroid; Q2W, once every 2 weeks; RR, risk ratio; SCS, systemic corticosteroid.

Learn more about how DUPIXENT can reduce steroid use